Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Motexafin gadolinium - Pharmacyclics

Next Previous
X
Search
Drug Profile

Motexafin gadolinium - Pharmacyclics

Alternative Names: API-GP3; FP-GP1; Gadolinium (III) texaphyrin; Gadolinium texaphyrin; Gd-Tex; Gd-texaphyrin; GdT2B2; MGd; PCI-0120; Xcytrin

Latest Information Update: 25 Sep 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmacyclics
  • Class Antineoplastics; Lanthanoid series elements; Metallotexaphyrins; Small molecules
  • Mechanism of Action Thioredoxin reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis; Brain cancer; Chronic lymphocytic leukaemia; Glioblastoma; Glioma; Head and neck cancer; Lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Renal cancer; Solid tumours

Most Recent Events

  • 01 Mar 2014 Pharmacyclics terminates a phase II trial in Chronic lymphocytic leukaemia and small lymphocytic lymphoma in USA (NCT00100711)
  • 13 Jun 2008 Final efficacy data from a phase I/II trial in non-Hodgkin's lymphoma released by Pharmacyclics
  • 21 Dec 2007 Pharmacyclics receives non-approvable letter from the FDA for motexafin gadolinium in combination with radiation for brain metastases arising from non-small cell lung cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top